Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.
Sponsor:
Mayo Clinic
Phase:
N/A
Contacts:
Clinical Trials Referral Officemayocliniccancerstudies@mayo.edu
855-776-0015
Government Study Link:
NCT05575440 - Click here to see study onClinicalTrials.gov
Help us improve your experience